SAR425899: Clinical Trials

5 completed, 1 withdrawn. 4 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 2	2	Completed 1, Withdrawn 1

Follow SAR425899: new trials by email Literature Review of SAR425899 trials Research Report on SAR425899

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease SAR425899, Placebo - Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus	Phase 2	Withdrawn	Sanofi		2019-05-23	2022-04-13
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects SAR425899, Placebo - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	24	2018-04-18	2022-04-25
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period SAR425899 - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	60	2018-01-19	2022-04-25
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer) - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	13	2017-12-20	2022-04-25
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus SAR425899, Placebo, Liraglutide - Type 2 Diabetes Mellitus	Phase 2	Completed	Sanofi	296	2016-12-02	2022-03-24
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients SAR425899, placebo, metformin - Type 2 Diabetes Mellitus	Phase 1	Completed	Sanofi	76	2015-03-01	2018-06-15

Conditions studied

Diabetes Mellitus, Type 2 (6)  ·  Non-alcoholic Fatty Liver Disease (1)

Sponsors

Sanofi (6)

Countries

United States (3)  ·  Germany (2)  ·  Canada (1)  ·  Czechia (1)  ·  Hungary (1)  ·  Mexico (1)  ·  Russia (1)  ·  Spain (1)  ·  Sweden (1)

Results publications

PMID 30091218, PMID 31679129, PMID 31808298, PMID 33822469, PMID 34503957

NIH funding

2017 (2), 2014 (1), 2016 (1)